Skip to main content
Premium Trial:

Request an Annual Quote

Riken-Genesis to Offer Advaita Gene Pathway Analysis Platform in Japan

NEW YORK (GenomeWeb) – Advaita Bioinformatics said today that it has entered into an exclusive partnership with Riken-Genesis to promote and sell Advaita's flagship product iPathwayGuide in Japan.

Under the agreement, iPathwayGuide will be a "featured informatics solution" for Riken-Genesis' customers, Advaita said.

Advaita's iPathwayGuide is a web-based application that takes data from next-generation sequencing and other gene expression experiments and performs an "impact analysis" to identify the gene pathways that are impacted in the given condition. Through this analysis, iPathwayGuide considers the type, role, and position of each gene in the pathway, as well as all the gene-gene signals at the system level, Advaita said.

Users can upload and analyze their data to the iPathwayGuide web application free of charge. The results of each analysis are available to the user for a period of time to assess their usefulness. If deemed useful, users may purchase unlimited access to the analysis results.

"We have already seen incredible interest for our software and this collaboration will provide a dedicated resource for Japanese customers," Advaita President and CEO Sorin Draghici said in a statement.

Riken-Genesis was established in 2007 as a Riken venture company and contract genomics analysis service provider, leveraging the genome analysis resources of Riken Research Institute.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more